The acquisition of Regulus Therapeutics, a California-based biotechnology company focused on microRNA therapies, by Novartis for $1.7 billion was a major strategic move to expand the latter’s research portfolio in RNA technology.

At the center of the deal is Dr. Stelios Papadopoulos, chairman of the board of Regulus, known for his extensive contributions to biotech (co-founder of Exelixis, Anadys, Regulus, and former chairman of Biogen). Stelios Papadopoulos, with his experience in managing innovative companies, played a critical role in negotiating the deal, enhancing Regulus’ value through its platform in pre-clinical and clinical programs.

The company has deep Greek roots, having been founded by Dr. Kleanthis Xanthopoulos, who served as CEO, led it to very successful partnerships with GlaxoSmithKline, Sanofi and AstraZeneca, and advanced its first molecules into clinical trials.

At the same time, Dr. Simos Simeonidis, a prominent scientist and investor with a 30-year career in biotechnology, co-founded Kos Biotechnology Partners (in which Stelios Papadopoulos is a lead advisor), the first Greek venture capital fund to invest exclusively in the life sciences sector in Greece, was the first analyst to cover Regulus in its IPO in 2012, invested in the company as a partner in Sarissa Capital Management in 2019 and served as a board member of Regulus, contributing to the strategic direction of the company, strengthening partnerships and fundraising.

Novartis, seeking innovative treatments for neurological and metabolic diseases, recognized Regulus’ potential, with the involvement of Papadopoulos, Xanthopoulos, and Simeonidis acting as a guarantee for the credibility and innovation of the venture. The deal strengthens Novartis’ position in the competitive RNA therapeutics space, while highlighting the importance of Greek business potential in the international biopharmaceutical industry.